Research Article

Prognostic Impact of Prephase Treatment Prior to First-Line Treatment in DLBCL: A Population-Based Registry Study

Table 1

Patient and tumour characteristics at diagnosis of diffuse large B-cell lymphoma.

All patients (N = 340)Before propensity score matchingAfter propensity score matching
With prephase (N = 126)Without prephase (N = 214)With prephase (N = 97)Without prephase (N = 97)

Age (median (min-max)), years65 [18–80]67 [20–80]65 [18–80]0.0667 [20–80]67 [19–80]1.00
Sex ratio (male/female)1.5 (204/136)1.7 (80/46)1.4 (124/90)0.311.7 (61/36)1.7 (61/36)1.00
Stage0.00050.86
 I-II91 (27%)20 (16%)71 (33%)19 (20%)20 (21%)
 III-IV249 (73%)106 (84%)143 (67%)78 (80%)77 (79%)
Stage B127 (37%)65 (52%)62 (29%)<0.000144 (45%)41 (42%)0.66
Bulky (X)138 (40%)67 (53%)71 (33%)0.000350 (52%)50 (52%)1.00
Serum LDH > normal200 (60%)92 (75%)108 (52%)<0.000168 (70%)65 (67%)0.64
PS<0.00010.44
 0-1251 (74%)66 (52%)185 (86%)64 (66%)69 (71%)
 >189 (26%)60 (48%)29 (14%)33 (34%)28 (29%)
aaIPI score<0.00010.53
 060 (18%)10 (8%)50 (24%)10 (10%)10 (10%)
 182 (25%)19 (16%)63 (30%)19 (20%)25 (26%)
 2123 (37%)48 (39%)75 (36%)44 (45%)41 (42%)
 367 (20%)46 (37%)21 (10%)24 (25%)21 (22%)
Place of care0.0480.64
 University hospitals223 (66%)91 (72%)132 (62%)66 (68%)69 (71%)
 Hospital centers117 (34%)35 (28%)82 (38%)31 (32%)28 (29%)

LDH, lactate dehydrogenase; PS, performance status; aaIPI, age-adjusted International Prognostic Index.